Taysha Gene Therapies Income from Continuous Operations 2020-2024 | TSHA

Taysha Gene Therapies income from continuous operations from 2020 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Taysha Gene Therapies Annual Income from Continuous Operations
(Millions of US $)
2023 $-112
2022 $-166
2021 $-175
2020 $-60
2019 $
Taysha Gene Therapies Quarterly Income from Continuous Operations
(Millions of US $)
2024-09-30 $-26
2024-06-30 $-21
2024-03-31 $-24
2023-12-31 $48
2023-09-30 $-117
2023-06-30 $-25
2023-03-31 $-18
2022-12-31 $-55
2022-09-30 $-27
2022-06-30 $-34
2022-03-31 $-50
2021-12-31 $-50
2021-09-30 $-51
2021-06-30 $-41
2021-03-31 $-32
2020-12-31 $-18
2020-09-30 $-15
2020-06-30 $-21
2020-03-31 $-5
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.434B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00